PROVEN EFFICACY IN A TEST-AND-TREAT SETTING
ROBUST EFFICACY, EVEN IN PLHIV WITH >1 MILLION copies/mL
Virological Outcomes by Baseline Viral Load or CD4+ T-cell Count at 48 Weeks (ITT–E Missing=Failure Analysis; Accounts for Patients Who May Have Switched Regimens)
DOVATO AS FIRST-LINE REGIMEN IN A TEST-AND-TREAT SETTING
STAT Study: Phase Iiib, Multicentre, Open-Label, Single-Arm, 52-Week Pilot Study Assessing Feasibility, Efficacy and Safety in Newly Diagnosed Adults
NEWLY DIAGNOSED PATIENTS WITH NO LAB RESULTS AT TREATMENT INITIATION
- Rolle C-P, Berhe M, Singh T, et al. High results of virologic suppression with DTG/3TC in newly diagnosed adults with HIV-1 infection and baseline viral load ≥500,000 c/mL: 48-week subgroup analysis of the STAT study. Presented at: IDWeek 2021; September 29-October 3, 2021; Virtual.
- Rolle C-P, Berhe M, Singh T, et al. Feasibility, efficacy, and safety of dolutegravir/lamivudine (DTG/ 3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV (PLWH): 48-week results of the STAT study. Presented at: The 11th International AIDS Society Conference on HIV Science; July 18-21, 2021; Virtual. Poster PEB182.
- Rolle C-P, Berhe M, Singh T, et al. Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. AIDS. 2021;35(12):1957-1965. doi:10.1097/QAD.0000000000002979